Equities Analysts Offer Predictions for PRCT Q3 Earnings

Key Points

• William Blair has issued a negative forecast, cutting PROCEPT BioRobotics' Q3 2025 earnings forecast from ($0.30) to ($0.45) per share.
• Despite the negative forecast, PROCEPT BioRobotics reported a revenue increase of 48.3% year-over-year, with last quarter's earnings slightly beating expectations at ($0.35) EPS against a consensus estimate of ($0.41).
• The stock has seen a reduction in price targets by analysts, with Piper Sandler and Wells Fargo lowering their objectives to $55.00 and $58.00, respectively.

PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) - Analysts at William Blair reduced their Q3 2025 EPS estimates for shares of PROCEPT BioRobotics in a research note issued to investors on Wednesday, August 6th. William Blair analyst B. Vazquez now expects that the company will earn ($0.45) per share for the quarter, down from their previous forecast of ($0.30). The consensus estimate for PROCEPT BioRobotics' current full-year earnings is ($1.75) per share. William Blair also issued estimates for PROCEPT BioRobotics' Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.49) EPS, Q1 2026 earnings at ($0.30) EPS, Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.75) EPS.

Several other equities research analysts have also commented on PRCT. Wall Street Zen upgraded PROCEPT BioRobotics from a "sell" rating to a "hold" rating in a research note on Saturday. Bank of America lowered their target price on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating for the company in a report on Friday, April 25th. Wells Fargo & Company cut their price objective on PROCEPT BioRobotics from $75.00 to $58.00 and set an "overweight" rating on the stock in a research report on Thursday, August 7th. Morgan Stanley dropped their price target on PROCEPT BioRobotics from $71.00 to $68.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 15th. Finally, Stephens assumed coverage on PROCEPT BioRobotics in a report on Wednesday, July 9th. They issued an "overweight" rating and a $70.00 price objective for the company. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $74.88.

PROCEPT BioRobotics Trading Down 0.4%

Shares of NASDAQ PRCT traded down $0.17 during trading hours on Monday, hitting $38.60. The company's stock had a trading volume of 1,237,357 shares, compared to its average volume of 1,025,018. The company has a debt-to-equity ratio of 0.13, a quick ratio of 7.86 and a current ratio of 9.21. The stock has a market cap of $2.15 billion, a price-to-earnings ratio of -24.90 and a beta of 1.05. The business has a 50-day simple moving average of $56.58 and a 200-day simple moving average of $58.52. PROCEPT BioRobotics has a 12 month low of $37.12 and a 12 month high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.41) by $0.06. PROCEPT BioRobotics had a negative net margin of 30.60% and a negative return on equity of 23.73%. The firm had revenue of $79.18 million for the quarter, compared to the consensus estimate of $75.67 million. During the same period in the previous year, the firm earned ($0.50) EPS. The business's revenue for the quarter was up 48.3% compared to the same quarter last year.

Insider Buying and Selling

In related news, Director Antal Rohit Desai sold 25,000 shares of the company's stock in a transaction on Thursday, June 12th. The shares were sold at an average price of $61.49, for a total value of $1,537,250.00. Following the completion of the sale, the director directly owned 14,363 shares in the company, valued at approximately $883,180.87. This represents a 63.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have sold 100,000 shares of company stock worth $6,271,250 over the last quarter. Insiders own 17.40% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. LPL Financial LLC increased its holdings in PROCEPT BioRobotics by 78.7% during the 4th quarter. LPL Financial LLC now owns 9,441 shares of the company's stock worth $760,000 after purchasing an additional 4,157 shares in the last quarter. Envestnet Asset Management Inc. lifted its stake in PROCEPT BioRobotics by 130.1% during the fourth quarter. Envestnet Asset Management Inc. now owns 42,202 shares of the company's stock worth $3,398,000 after purchasing an additional 23,861 shares during the last quarter. Invesco Ltd. raised its holdings in shares of PROCEPT BioRobotics by 86.2% during the 4th quarter. Invesco Ltd. now owns 499,949 shares of the company's stock worth $40,256,000 after buying an additional 231,470 shares in the last quarter. Renaissance Technologies LLC acquired a new position in PROCEPT BioRobotics during the 4th quarter worth approximately $22,422,000. Finally, Raymond James Financial Inc. acquired a new position in shares of PROCEPT BioRobotics during the fourth quarter worth $1,647,000. 89.46% of the stock is owned by institutional investors.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).